Wrapping up Q4 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including ...

Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results , but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the ...

In recent trading, shares of 10x Genomics Inc (Symbol: TXG) have crossed above the average analyst 12-month target price of $12.82, changing hands for $13.01/share. When a stock reaches the target an ...

Pleasanton, Calif.-based biotechnology startup 10x Genomics went public on Sept. 12, opening on the Nasdaq Stock Market at a price of $39 per share. The company’s initial public offering price was ...

10x Genomics, Inc. (NASDAQ:TXG) reported a loss for the third quarter on Tuesday. The company posted a quarterly loss of 30 cents per share, compared to market expectations for a loss of 34 cents per ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

In the assessment of 12-month price targets, analysts unveil insights for 10x Genomics, presenting an average target of ...

PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to ...